Similar articles for PMID: 18456775

Year	Number of Results
2001	4
2003	4
2005	6
2006	12
2007	18
2008	11
2009	5
2010	10
2011	11
2012	1
2013	4
2014	3
2015	1
2018	1
2019	2
2021	2
2022	1
2023	1
2024	0

1

Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Pestalozzi B, Castiglione M; ESMO Guidelines Working Group. Pestalozzi B, et al. Ann Oncol. 2008 May;19 Suppl 2:ii7-10. doi: 10.1093/annonc/mdn071. Ann Oncol. 2008. PMID: 18456775 Free article. No abstract available.

2

Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.

Baselga J, Perez EA, Pienkowski T, Bell R. Baselga J, et al. Oncologist. 2006;11 Suppl 1:4-12. doi: 10.1634/theoncologist.11-90001-4. Oncologist. 2006. PMID: 16971734 Free article. Review.

3

[Adjuvant therapy with trastuzumab (Herceptin) in primary breast cancer].

Huober J, Jackisch C, Untch M, Möbus V, Wallwiener D, Kaufmann M, Minkwitz G. Huober J, et al. Zentralbl Gynakol. 2006 Feb;128(1):30-7. doi: 10.1055/s-2006-921382. Zentralbl Gynakol. 2006. PMID: 16450285 German.

4

Her2 and trastuzumab in breast cancer.

Horton J. Horton J. Cancer Control. 2001 Jan-Feb;8(1):103-10. doi: 10.1177/107327480100800113. Cancer Control. 2001. PMID: 11176040 Free article. Review. No abstract available.

5

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R; Herceptin Adjuvant (HERA) Trial Study Team. Gianni L, et al. Lancet Oncol. 2011 Mar;12(3):236-44. doi: 10.1016/S1470-2045(11)70033-X. Epub 2011 Feb 25. Lancet Oncol. 2011. PMID: 21354370 Clinical Trial.

6

Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

ESMO Guidelines Working Group; Pestalozzi B. ESMO Guidelines Working Group, et al. Ann Oncol. 2007 Apr;18 Suppl 2:ii5-8. doi: 10.1093/annonc/mdm015. Ann Oncol. 2007. PMID: 17491045 Free article. No abstract available.

7

ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer.

ESMO. ESMO. Ann Oncol. 2001 Aug;12(8):1047-8. doi: 10.1023/a:1017448816215. Ann Oncol. 2001. PMID: 11583179 Free article. No abstract available.

8

Adjuvant trastuzumab in early breast cancer.

Mariani G, Gianni L. Mariani G, et al. Ann Oncol. 2006 Sep;17 Suppl 10:x54-8. doi: 10.1093/annonc/mdl237. Ann Oncol. 2006. PMID: 17018752 Free article. Review. No abstract available.

9

Phase I/II study of treatment of stage IV breast cancer with OKT3 x trastuzumab-armed activated T cells.

Lum LG, Rathore R, Cummings F, Colvin GA, Radie-Keane K, Maizel A, Quesenberry PJ, Elfenbein GJ. Lum LG, et al. Clin Breast Cancer. 2003 Aug;4(3):212-7. doi: 10.3816/cbc.2003.n.028. Clin Breast Cancer. 2003. PMID: 14499016 Clinical Trial. No abstract available.

10

Reviewing prognostic factors in breast cancer management.

Glissmeyer M. Glissmeyer M. JAAPA. 2007 May;20(5):42-6. doi: 10.1097/01720610-200705000-00009. JAAPA. 2007. PMID: 17546943 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

93 results

Results by year